Celldex Therapeutics logo

Celldex TherapeuticsNASDAQ: CLDX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 May 1986

Next earnings report:

26 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.69 B
-48%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-77%vs. 3y high
58%vs. sector
203.45
-90%vs. 3y high
96%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:47:43 GMT
$25.48-$0.58(-2.23%)

Dividend

No data over the past 3 years
$2.50 M$830.00 K
$2.50 M-$35.84 M

Analysts recommendations

Institutional Ownership

CLDX Latest News

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
globenewswire.com26 October 2024 Sentiment: POSITIVE

HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
globenewswire.com25 October 2024 Sentiment: POSITIVE

HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD)—will be presented in a late breaking oral presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting being held in Boston October 24-28, 2024.

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
zacks.com26 September 2024 Sentiment: NEUTRAL

Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
globenewswire.com16 September 2024 Sentiment: POSITIVE

HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024.

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com08 August 2024 Sentiment: NEUTRAL

HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
globenewswire.com29 July 2024 Sentiment: POSITIVE

HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.

Celldex Therapeutics to Present at Jefferies Healthcare Conference
globenewswire.com04 June 2024 Sentiment: POSITIVE

HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
zacks.com27 May 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Zacks Investment Research09 April 2024 Sentiment: POSITIVE

The intense selling pressure for Celldex (CLDX) appears to have eased as it is now considered oversold from a technical standpoint. Furthermore, the consensus among Wall Street analysts in raising earnings estimates suggests that the stock is poised for a turnaround.

  • 1(current)

What type of business is Celldex Therapeutics?

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

What sector is Celldex Therapeutics in?

Celldex Therapeutics is in the Healthcare sector

What industry is Celldex Therapeutics in?

Celldex Therapeutics is in the Biotechnology industry

What country is Celldex Therapeutics from?

Celldex Therapeutics is headquartered in United States

When did Celldex Therapeutics go public?

Celldex Therapeutics initial public offering (IPO) was on 15 May 1986

What is Celldex Therapeutics website?

https://www.celldex.com

Is Celldex Therapeutics in the S&P 500?

No, Celldex Therapeutics is not included in the S&P 500 index

Is Celldex Therapeutics in the NASDAQ 100?

No, Celldex Therapeutics is not included in the NASDAQ 100 index

Is Celldex Therapeutics in the Dow Jones?

No, Celldex Therapeutics is not included in the Dow Jones index

When was Celldex Therapeutics the previous earnings report?

No data

When does Celldex Therapeutics earnings report?

The next expected earnings date for Celldex Therapeutics is 26 February 2025